Figures & data
Table 1 Baseline characteristics of type 2 diabetes patients who received newly prescribed dapagliflozin in primary care practices in Germany (Disease Analyzer)
Table 2 Three-month (after the ID) changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy in primary care practices in Germany
Table 3 Six-month (after the ID) changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy in primary care practices in Germany
Figure 1 Scatter plot representing the relationship between the change in HbA1c (%) and body weight (kg) after 3 months in type 2 diabetes patients initiating dapagliflozin treatment in primary care practices.
![Figure 1 Scatter plot representing the relationship between the change in HbA1c (%) and body weight (kg) after 3 months in type 2 diabetes patients initiating dapagliflozin treatment in primary care practices.](/cms/asset/8689d837-8d15-4a91-978a-98e6d57b4535/dmso_a_116243_f0001_c.jpg)
Figure 2 Scatter plot representing the relationship between the change in HbA1c (%) and weight (kg) after 6 months in type 2 diabetes patients initiating dapagliflozin treatment in primary care practices.
![Figure 2 Scatter plot representing the relationship between the change in HbA1c (%) and weight (kg) after 6 months in type 2 diabetes patients initiating dapagliflozin treatment in primary care practices.](/cms/asset/78f64d48-134d-4e7a-9739-bb5ef36358e8/dmso_a_116243_f0002_c.jpg)
Table 4 Variables associated with HbA1c (%) change after 3 and 6 months in type 2 diabetes patients initiating dapagliflozin in primary care practices: multivariate linear regression models
Table 5 Variables associated with body weight change (kg) after 3 and 6 months in type 2 diabetes patients initiating dapagliflozin in primary care practices: multivariate linear regression model
Table S1 Three-month changes (after the ID) in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy in primary care practices in Germany
Table S2 Six-month changes (after the ID) in HbA1c, body weight (kg), and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy in primary care practices in Germany